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Editorial on the Research Topic
Nanoparticle Vaccines Against Infectious Diseases
Vaccines remain the most realistic means of controlling, eliminating, and eventually completely
eradicating an infectious disease. Many vaccines have been successfully implemented over
the course of recent medical history and some have succeeded in completely (small pox) or
near-completely eradicating (polio) their target diseases. However, many human pathogens are still
in need of an effective vaccine, including viruses such as human immunodeficiency (HIV), herpes
simplex (HSV), respiratory syncytial (RSV), Chikungunya, Dengue, Ebola, andHepatitis C; bacteria
such as Mycobacterium tuberculosis or Salmonella dysenteriae and parasites such as Plasmodium
spp., to name a few.
Challenges in developing an effective vaccine against these infectious diseases are multiple,
ranging from antigenic variability (HIV), multiple genotypes or serotypes (Norovirus, Dengue,
Influenza), complex pathogenesis or life cycle of pathogen (tuberculosis, malaria), lack of correlates
of protection (TB) and finally, the paucity of the adjuvants and delivery systems suitable for
human application. With regards to the latter, it is true to say that non-live, subunit vaccine
development has been historically severely hampered by safety issues associated with the adjuvants
and delivery systems.
Nanoparticles (NPs) have emerged as a promising approach for vaccine delivery as both
antigen delivery platform and immunomodulators. Their use in vaccine candidates from early
preclinical to late stage clinical testing is a testament to their success as a promising, new
approach, alongside the more conventional protein plus adjuvant, viral vector, or attenuated whole
organism vaccine approaches. There are many different types of NPs, both synthetic and natural,
as well as further varieties that are not considered classically as NPs, but are physically and
functionally closely related to them, such as liposomes, virus-like particles, bacterial spores, and
immunostimulating complexes.
The ability of NPs to interact with immune components and to induce humoral and cellular
immune responses make them particularly amenable for vaccine design. Furthermore, they have
been successfully applied by different routes (systemic and throughout the mucosa), and have been
demonstrated capable of modifying and broadening of the immune profiles. They can increase
antigen stability (time, temperature, proteolysis) and confer substantial flexibility to vaccine
formulation, allowing the incorporation of diverse antigens and immunostimulants, compared to
conventional subunit/adjuvant vaccines.
Many of these advantages are highlighted in this Research Topic but it is also necessary to
draw attention to the areas for further improvements, including a better understanding of the
mechanisms of NPs vaccine immunogenicity and a more efficient antigen presentation by the
molecular histocompatibility complex molecules, especially the so called cross-presentation by
class I molecules performed by specialized dendritic cells, following the endocytic/phagocytic
uptake of NPs. Also, and very importantly, NPs design and technology may need to be
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further improved to allow for an “off-the-shelf ” approach to
their application and testing rather than the complex and
time/resource demanding process of customized production.
In this Research Topic, we include several articles that focus
on NP-based vaccine delivery against infectious diseases and
also review articles that summarize and critically assess the
progress that has been achieved so far in the specific areas of
NP vaccine development. It is hoped that the presented evidence
will deepen our understanding of their mode of action and the
overall potential of NPs for translation of this vaccine approach
to human application.
Thus, Kim et al. reported a novel method of generating bio-
designed NPs utilizing a bacterial expression system and the
capacity of RNA molecules to act as chaperones. Using Middle
East respiratory syndrome-coronavirus (MERS-CoV) as the
infection target, they demonstrated that NPs can be assembled
in the expression host and that this was entirely dependent
on chaperoning capacity of RNA since mutations in the RNA-
binding domain abolished formation of NPs. The resulting NPs
were immunogenic in mice and induced blocking antibodies
against MERS virus. This approach of generating protein-only
based NPs could be further optimized (i.e., in terms of yields and
homogeneity) and developed as a generic NPs platform against
other infectious diseases.
In another article, the utility of mucosally delivered chitosan-
based vaccine against swine influenza A virus (SwIAV) was
demonstrated by Dhakal et al., who reported that strong cross-
reactive mucosal IgA and cellular immune responses in the
respiratory tract were induced in young piglets using this
vaccination approach. Intranasal delivery of these NPs loaded
with SwIAV antigens resulted in a reduced nasal viral shedding
and lung virus titres in pigs, suggesting that this vaccination
approach could offer a broader coverage than the current
attenuated strain-specific SwIAV.
Chitosan was also tested, alongside arginine-rich
protamine (PR) and polyarginine (PARG)-based NPs
in a more mechanistic in our own studies (Peleteiro
et al.), reporting that PR and PARG showed a superior
immunomodulating ability, as measured by enhanced reactive
oxygen species production, activation of the complement
cascade, cytokine production, and mitogen-activated protein
(MAP) kinases/nuclear factor κB activation. When complexed
with recombinant Hepatitis B glycoprotein, and compared
against each other, protamine-based NPs elicited higher IgG
levels than PARG NPs.
The utility of NPs as a delivery system for immunododulators
and adjuvants rather than antigens was illustrated in the article
by Takahashi et al. They showed that the biodegradable carbonate
apatite (CA)-based nanoparticles can serve as the delivery system
for the CpG oligodeoxynucleotide (CpG ODN) adjuvant and
that this combination was more potent in activating dendritic
cells and induced more diverse cytokine profiles than CpG ODN
alone. When used with a model antigen, the NPs/CpG ODN
induced higher level humoral and cellular immune responses
in mice, and in particular enhanced CD8+ T cell responses,
suggesting that this vaccination approach is particularly suitable
for viral infections which require cytotoxic T cells alongside the
neutralizing antibodies to control the viremia.
Another example of the benefit of combining NPs with
adjuvants was provided also in the study by Malik et al.,
who showed that an anthrax antigen when combined with
trimethyl-chitosan nanoparticles (TMC-PA) and either
CpG ODN or polyinosinic: polycytidylic acid (Poly I:C)
adjuvant induced higher immune responses in mice than
any other combination in that vaccine formulation. In
a different approach, Wagner-Muniz et al. reported that
laboratory-generated polyanhydride nanoparticles based on
1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-
bis-(p-carboxyphenoxy)hexane (CPH) and sebacic acid (SA),
could be employed as an effective vaccination strategy against
Streptococcus pneumoniae, with strong immune responses
and good-level of protection after the challenge of mice with
the bacteria.
Finally, in our own studies (Copland et al.), we demonstrated
that mucosal delivery of a mycobacterial poly-antigen coated
onto heat-inactivated Bacillus subtilis spores (“Spore-FP1”)
induced systemic and mucosal immune responses in mice,
characterized with elevated antigen-specific IgG and IgA titres in
the serum and bronchoalveolar lavage, antigen-specific memory
T-cell proliferation in both CD4+ and CD8+ compartments,
and resident memory T cells accumulation in the lungs. When
used to boost the current TB vaccine, BCG, this vaccine
candidate provided superior protection in mice challenged with
aerosolisedM. tuberculosis.
In addition, the collection also includes two review articles
on lipid-based particles as a highly versatile vaccine delivery
system. Thus, Corthesy and Bioley reviewed the potential
of liposomes and liposomes derivatives as mucosal vaccine
delivery systems, while Nisini et al. performed a critical
assessment regarding the application of liposomes in a
broader context of infectious diseases. Gao et al. provided
an extensive review of the current state of virus-like particles
(VLP) as an emerging and highly attractive vaccine delivery
system, focusing in particular on the use of VLP in the
context of HIV infection. And finally, Pati et al. reviewed
the current state of NPs-based vaccines against infectious
diseases, highlighting the key challenges and the potential for
further progress.
The promising results obtained with several type of NPs
highlight the potential of this vaccine approach for the
development of new vaccines in the near future. However, further
studies are still required to address in greater detail the issues
regarding their safety, immunogenicity, stability, cost, scaling-up
potential, and the use of appropriate animal models and clinical
assays in humans. Even so, the significant body of evidence
already generated, as partly illustrated in this Research Topic,
underscores the translational potential of NPs in vaccine research
and development, not only in the context of infectious diseases
but potentially also other conditions such as autoimmune
diseases and cancer.
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